AG
Artal Group Portfolio holdings
AUM
$930M
1-Year Return
3.57%
This Quarter Return
+5.69%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$1.68B
AUM Growth
-$52M
(-3%)
Cap. Flow
-$36.3M
Cap. Flow
% of AUM
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
48.34%
Holding
151
New
26
Increased
23
Reduced
13
Closed
33
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$23.2M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$20.9M |
| 3 |
Ventyx Biosciences
VTYX
|
$18M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$13.1M |
| 5 |
Cytokinetics
CYTK
|
$12.9M |
Top Sells
Sector Composition
| 1 | Healthcare | 94.05% |
| 2 | Consumer Discretionary | 5.18% |
| 3 | Real Estate | 0.31% |
| 4 | Financials | 0.29% |
| 5 | Technology | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Ventyx Biosciences
VTYX
$185M
| $18M | 1.07% |
+535,812
| New | +$18M |
|
|
OMGA
27
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $15.3M | 0.91% |
2,533,045
+259,515
| +11% | +$1.56M |
|
28
Vor Biopharma
VOR
$244M
| $15M | 0.89% |
2,792,805
-82,776
| -3% | -$445K |
|
29
Fate Therapeutics
FATE
$112M
| $14.8M | 0.88% |
2,600,000
| – | – |
|
30
Erasca
ERAS
$420M
| $14.2M | 0.84% |
4,721,194
+10,512
| +0.2% | +$31.6K |
|
|
RXDX
31
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $13.1M | 0.78% |
+121,756
| New | +$13.1M |
|
32
Wave Life Sciences
WVE
$1.3B
| $13M | 0.77% |
3,000,000
| – | – |
|
33
Viridian Therapeutics
VRDN
$1.52B
| $12.8M | 0.76% |
+504,978
| New | +$12.8M |
|
34
Generation Bio
GBIO
$38.9M
| $12.1M | 0.72% |
281,419
| – | – |
|
35
Geron
GERN
$880M
| $12.1M | 0.72% |
+5,565,889
| New | +$12.1M |
|
36
Travere Therapeutics
TVTX
$1.89B
| $11.5M | 0.68% |
511,784
+11,784
| +2% | +$265K |
|
37
Natera
NTRA
$22.9B
| $11.1M | 0.66% |
200,000
| – | – |
|
38
Aurinia Pharmaceuticals
AUPH
$1.65B
| $11M | 0.65% |
1,000,000
| – | – |
|
|
CBIO
39
Crescent Biopharma, Inc. Common Stock
CBIO
$190M
| $10.8M | 0.64% |
+85,891
| New | +$10.8M |
|
40
Foghorn Therapeutics
FHTX
$305M
| $10.7M | 0.63% |
1,720,720
| – | – |
|
41
Intellia Therapeutics
NTLA
$1.25B
| $10.3M | 0.61% |
276,077
+1,077
| +0.4% | +$40.1K |
|
|
ALPN
42
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $9.21M | 0.55% |
1,193,030
| – | – |
|
|
ARAV
43
DELISTED
Aravive, Inc. Common Stock
ARAV
| $9.15M | 0.54% |
4,572,515
| – | – |
|
44
Mersana Therapeutics
MRSN
$35.5M
| $9.11M | 0.54% |
88,632
+632
| +0.7% | +$64.9K |
|
45
Replimune Group
REPL
$454M
| $8.83M | 0.52% |
500,000
-200,000
| -29% | -$3.53M |
|
46
BridgeBio Pharma
BBIO
$9.91B
| $8.29M | 0.49% |
500,000
+250,000
| +100% | +$4.15M |
|
47
Avidity Biosciences
RNA
$6.24B
| $7.86M | 0.47% |
511,962
+11,962
| +2% | +$184K |
|
48
TG Therapeutics
TGTX
$5.06B
| $7.69M | 0.46% |
+511,389
| New | +$7.69M |
|
|
TSVT
49
DELISTED
2seventy bio
TSVT
| $7.65M | 0.45% |
+750,000
| New | +$7.65M |
|
50
89bio
ETNB
$1.28B
| $7.62M | 0.45% |
500,000
+100,000
| +25% | +$1.52M |
|